Metsera (MTSR) Stock Price, News & Analysis

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Key Stats

• Today's Range: $37.29 to $40.95
• 50-Day Range: $25.38 to $44.30
• 52-Week Range: $12.30 to $47.40
• Volume: 1.02 million shs
• Average Volume: 752,554 shs
• Market Capitalization: $4.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

MTSR Stock Analysis - Frequently Asked Questions

How have MTSR shares performed this year?

Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR shares have increased by 37.2% and is now trading at $40.47.

How were Metsera's earnings last quarter?

Metsera Inc. (NASDAQ:MTSR) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.03) EPS for the quarter.

When did Metsera IPO?

Metsera (MTSR) raised $275 million in an IPO on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

When does the company's lock-up period expire?

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Metsera's major shareholders?

Metsera's top institutional investors include Exchange Traded Concepts LLC (0.04%) and KLP Kapitalforvaltning AS.

How do I buy shares of Metsera?

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTSR
• Previous Symbol: NASDAQ:MTSR
• CIK: 2040807
• Web: N/A
• Phone: (212) 784-6595
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Metsera: $55.00
• High Price Target: $65.00
• Low Price Target: $38.00
• Potential Upside/Downside: +35.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.55
• Quick Ratio: 6.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.46) per share
• Price / Book: -16.45

Miscellaneous

• Outstanding Shares: 105,060,000
• Free Float: N/A
• Market Cap: $4.25 billion
• Optionable: N/A
• Beta: N/A